Interim Data to be Presented at Upcoming American Spinal Injury Association Conference
NEWARK, Calif., April 17, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company’s Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.’s proprietary HuCNS-SC® human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve subjects with chest-level injury to the spinal cord. The trial enrolled seven patients with complete paralysis, no motor or sensory function below the point of injury, classified as complete (AIS A), according to the American Spinal Injury Association Impairment Scale, and five patients with no motor function and limited sensory function below the point of injury classified as incomplete (AIS B). Zurich study site principal investigator, Dr. Armin Curt, will present an interim update based on six month data for the first six subjects at the American Spinal Injury Association conference this coming May. Final results from this landmark study are expected to be released mid-2015.